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Mammalian perchloric acid-soluble liver extracts (Lévy-Favatier et
al, 1993; Bartorelli et al, 1994; Oka et al, 1995; Ceciliani et al,
1996a), as well as a trichloroacetic acid-soluble extract from
human mononuclear monocytes (Schmiedeknecht et al, 1996),
have been shown to contain a protein with an unidentified function
that may participate in cell differentiation and degeneration through
regulation of protein synthesis. Vivacious tumour expression of this
new family of proteins suggests that it may be involved in immune
control of tumour growth (Bartorelli A et al, 1996). UK101, a
perchloric goat liver extract, contains three main electrophoreti-
cally distinguishable bands of about 8.5, 14 and 50 kDa. The first
seems to be ubiquitin and the second a protein of the new family,
whereas the third, a glycoprotein with mannose residues, has not
yet been fully defined (Ceciliani et al, 1996b). Attention has been
primarily directed to the 14-kDa band (denominated UK114). Its
role in tumour cell proliferation, however, is still uncertain.
Complement-mediated cytotoxic activity has been demonstrated in
the sera of UK114-treated animals (Bartorelli A et al, 1996), and
both cytolysis and tumour inhibition have been observed in the sera
of cancer patients (Bussolati et al, 1997). The therapeutic effect of
UK101 and UK114 in experimental mammalian tumours has been
studied (Bartorelli et al, 1994; Racca et al, 1997), whereas their role
in the prevention of carcinogenesis has not been investigated.
Oral cancer (ICD9 140–149) is the sixth most common
neoplasm worldwide (Parkin et al, 1993). We have devoted our
attention to growth inhibition of its experimental analogue in
animals.
The Syrian hamster has been used in experimental studies of
various mouth diseases. It has long been known (Salley, 1954) that
squamous cell carcinomas can be produced in the cheek pouches
of hamsters by multiple brushings with chemicals such as
dimethylbenzanthracene (DMBA), and they have, therefore, been
extensively considered in investigation of mucosal malignancies
(Shklar, 1972). Use of the hamster model has led to the recognition
of substances that can be used to prevent these tumours, such as
retinoic acid (Gilmore and Giunta, 1981), vitamin E (Trickler and
Shklar, 1987), extracts of Spirulina–Dunaliella algae (Schwartz et
al, 1988), bacille bilié de Calmette–Guérin (BCG) (Giunta et al,
1974) and levamisole (Eisenberg and Shklar, 1977). A recent
analysis of p53 gene expression (Gimenez-Conti et al, 1996) has
also shown that the hamster cheek-pouch model is better than the
mouse skin two-phase carcinogenesis model (Odukoya and
Shklar, 1982) in the investigation to study human oral carcino-
genesis due to smoke, smokeless tobacco and alcohol abuse.
The present paper assesses the ability of UK101 to inhibit
carcinogenesis of DMBA-induced Syrian hamster cheek-pouch
squamous cell carcinoma. The positive control was provided 
by animals subjected to an active immune treatment (BCG).
Counteraction of the effect of UK101 by the corticosteroid
hormone dexamethasone (DM) was also investigated.
MATERIALS AND METHODS
Animals and treatment
Animals were treated in accordance with the Italian legislation on
animal experiments and under strict veterinary control in keeping
with the UKCCCR guidelines.
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Thirty-six 30- to 40-day-old male Syrian hamsters weighing
about 50 g were randomly divided into five groups: control [eight
animals treated with phosphate-buffered saline (PBS)], BCG
(Pasteur-Mérieux, France) (eight treated with 1´103 culturable
BCG particles diluted in PBS), UK101 (Sicor, Italy) (eight treated
with 20 mg UK101 diluted in PBS), UK101 + DM (eight treated
with 20 mg UK101 diluted in PBS plus 10 mg DM diluted in PBS,
not mixed in the same syringe) and DM (four treated with 10 mg
DM). The first three groups were blind treated. Each animal
received 1 ml volume once a week subcutaneously during the
whole course of the experiment, except for DM (twice a week
owing to its biological half-life) (Schimmer and Parker, 1996).
After 4 weeks from the beginning of subcutaneous administra-
tions, the right cheek pouch of fasting animals was painted three
times a week with 0.5% DMBA (Sigma, Italy) in paraffin oil.
Animals were inspected for the presence of tumours once a week.
After 18 weeks from the beginning of tumour induction, when
frank tumours were evident in 100% of one of the first blind
groups, the animals were killed by carotid bleeding under carbon
dioxide anaesthesia. Their right cheek pouches were macroscopi-
cally examined to count and measure exophytic tumours and
remove them for histological examination.
Tumours were grouped according to their major diameter as less
or more than 2 mm (limit of macroscopic examination). The left
pouches were also searched for tumours and none were found. The
animals were then dissected for macroscopic examination of their
principal organs. These were free from evident abnormalities.
Although by macro- and microscopic examination no endophytic
lesions were observed in the UK-treated animals, whereas endo-
phytic lesions in the controls were always associated with the
exophytic ones in the same area, the simplest, most objective and
evident way of considering exophytic lesions only was chosen.
Histology and immunocytochemical staining of
proliferating cells
Specimens of tumours and left pouch mucosa were fixed in
Carnoy’s fluid or in formalin at 4°C for 12 h and embedded in
paraffin. Sections (4 mm thick) were stained with haematoxylin
and eosin. For immunocytochemistry, histologically normal areas
were selected from the DMBA-treated mucosa of both controls
and UK101-treated animals. Sections were stained with the Mib-5
monoclonal antibody (Immunotech, France) which reacts with the
proliferation-associated Ki-67 antigen (Schluter et al, 1993). The
antibody was diluted 1:10 in PBS and used after microwave treat-
ment in citrate buffer. Nuclei were counterstained with haemalum.
The thickness of the epithelium was similar in the two groups and
ranged from 45 to 85 mm (mean 65 mm). Positive nuclei were
counted in the basal and Malpighian layers over a length of epithe-
lium of 250 mm from several sections and cases. Thirty-two speci-
mens were obtained from three control animals and 56 obtained
from seven UK101 animals.
Electrophoresis
Standard techniques were employed for sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot
analysis (Sambrook et al, 1989) by using the enhanced chemilumi-
nescence (ECL) detection system (Amersham, UK): rabbit poly-
clonal antibodies, 1:200 (Bartorelli et al, 1996), and commercial
mouse monoclonal antibodies (Chemicon International, USA)
were used to stain UK101 and ubiquitin, respectively, the former
being recognized by horseradish peroxidase-protein A (Biorad,
USA) and the latter by horseradish peroxidase-sheep anti-mouse
(Amersham). Moreover, sera from UK-treated animals, 1:50,
recognized by horseradish peroxidase–protein A, were also used
to stain UK101 proteins. Ubiquitin was obtained from bovine red
blood cells (Sigma).
Cytotoxicity
Hamster sera were collected, decomplemented by heating for 1 h
at 56°C and stored at –20°C until use. Human gastric cancer cells
Kato III, expressing UK114 protein on their surface, and T47D,
negative for UK114 expression, were labelled with 3.7 MBq of
[51Cr]sodium chromate for 1 h at 37°C and washed to remove
extracellular  51Cr. Aliquots of the labelled cells were placed in 96-
well microplates (5´104 per 50 ml) and incubated for 5 h at 37°C
with 50 ml of human serum at different concentrations in the pres-
ence of 10 ml of guinea pig complement (Sigma). Hyperimmune
rabbit serum raised against UK114 protein was used as positive
control. To evaluate the complement dependency of the reaction,
control experiments were performed in the absence of comple-
ment. After centrifugation, release of 51Cr in the supernatant was
counted. The percentage of specific cytolysis was calculated from
the count of experimental release, total release and spontaneous
release (Bartorelli et al, 1996).
Statistics
Analysis of variance was used (Armitage, 1971).
RESULTS
Photographs of right internal mucosa with cheek-pouch tumours in
the control, BCG, UK101 + DM, and UK101 groups are presented
in Figure 1. Microphotographs of examples from the control and
treated groups (Figure 2) show that the control displays features of
epidermoid carcinoma, very similar to those of the UK101 + DM
group, with the exception of abundant stromal tissue in the latter,
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Figure 1 Hamster right cheek-pouches treated with DMBA. (A) Control, 
(B) BCG, (C) UK101 + DM, and (D) UK101. Length unit: cm56 F Ghezzo et al
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whereas BCG tumour shows less marked signs of malignancy and
that of the UK101 group was the least malignant. Tumours of the
DM group, not reported in the figures, were indistinguishable from
control. Table 1 summarizes the characteristics of these specimens.
Inhibition of the tumour growth in the UK101-treated animals
could be related to a lower proliferation of the epithelial layer. To
test this hypothesis, we established an immunocytochemical
procedure using the Mib5 antibody revealing the proliferation-
associated Ki-67 nuclear antigen (Figure 3). Values obtained in
histologically normal areas of the DMBA-treated mucosa of both
controls and UK101-treated tests were compared. Values were
significantly different (P < 0.0001) in controls (mean 22.8 ± 5.3)
and in UK101-treated animals (10.7 ± 2.8). In Figure 4, SDS-
PAGE and Western blotting of the UK101 preparation together
with ubiquitin are shown. As expected, UK101 SDS-PAGE shows
three main bands of 50, 14 and 8.5 kDa respectively. The last
molecular weight was coincident with that of ubiquitin. Western
blotting analysis with rabbit anti-UK101 antibodies shows clearly
the two main bands of the SDS-PAGE at 14 and 50 kDa, together
with a fainter band at about 30 kDa. The absence of the band
evident at 8.5 kDa in the SDS-PAGE is probably indicative of the
poor antigenic power of the small ubiquitin molecule. A Western
blot with mouse monoclonal antibodies against ubiquitin shows
the identity of the third band with ubiquitin. In the last lane of the
same table, an example of UK101 stained by serum of a UK-
treated animal is also reported. The presence of only one band
could be evidence of the poorly antigenic power of the UK114
fraction when Freund’s adjuvant is not employed.
The tumour numbers and sizes in the five groups are listed in
Table 2. Both UK101-treated and, to a significantly lesser extent,
BCG-treated animals showed fewer tumours than the controls. The
UK101+DM and DM groups resembled the controls. The inci-
dence of the small (<2 mm) and the large (>2 mm) tumours was
statistically similar.
Table 3 shows the results of the cytotoxicity experiments. Sera
from the UK101 group displayed greater cytotoxicity than sera
from the controls and BCG when UK114-positive Kato III cells
were used. The cytotoxic effect was absent when UK114-negative
T47D cells were used (data not shown). DM seemed to completely
reverse the effect of UK101.
DISCUSSION
As observed by other authors, DMBA painting of hamster cheek
pouches produced tumours very similar to human squamous cell
carcinoma of the oral cavity, and BCG was able to oppose this
carcinogenetic mechanism. UK101 was stronger than BCG in
inhibiting carcinogenesis. The immunocytochemical data also
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Figure 2 Histological examination of hamster cheek-pouch tumours. 
(A) Control, bar=125 mm; (B) BCG, bar=200 mm; (C) UK101 + DM, 
bar=200 mm; (D) UK101, bar=200 mm
Table 1 Microscopic characteristics of right cheek-pouch carcinomas
Group Stroma Vessels Horn pearl Hyalinosis Nuclear Local
atypia malignancy
Control and DM + ++ ++/+++ + ++/+++ +
BCG + + ++ + + –/+
UK101 + –/+ –/+ –/+ –/+ –
UK101 + DM ++/+++ ++ ++/+ + +++/++ –/+
–, Absent; +, barely present; ++, present; +++, abundant.
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Figure 3 Immunochemical staining of proliferating cells of histologically
normal mucosa. (A) Control animals. (B) UK101-treated animals. Bar=80 mm
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– 21.5
Figure 4 (A) SDS-PAGE of the UK101 mixture and of ubiquitin. 
(B) Western blot analysis of UK101 and ubiquitin stained with anti-UK101
rabbit polyclonal antibodies. (C) Western blot analysis of UK101 and
ubiquitin stained with mouse monoclonal antibodies against ubiquitin. (D)
Western blot analysis of UK101 stained by UK101-treated hamster serumGoat liver extract and hamster cheek-pouch carcinoma 57
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show active inhibition of proliferation of the epithelial layer by
UK101 when tumour lesions are not yet evident, suggesting the
presence of a mechanism of action able to act in the early phases of
carcinogenesis. However, because no particular difference could
be observed in the incidence of small and large tumours, it may be
suggested that UK101 is also effective in the late stages of tumour
growth. A direct effect of UK101 on the activation and alkylating
mechanisms of DMBA cannot be ruled out. Although corticos-
teroids have many types of actions, the observation that DM
reversed the effect of UK101, as shown by the absence of a signif-
icant difference between the control and the UK101+DM groups,
may reflect the result of an immunosuppressive action of the drug,
suggesting involvement of the immune system in UK101 anti-
tumour activity. Elucidation of the precise mechanism of action of
glucocorticoids is beyond the purpose of this work. Even so, DM
opposition to anti-tumour activity against the product of the action
of DMBA rather than against the action of DMBA itself seems the
more reasonable hypothesis. In either event, the phenomenon
lends support to the reflection that the use of corticosteroids may
not be indifferent to the efficacy of the antitumoral therapy. The
cytotoxicity data are further evidence in favour of a stimulus of
serum anti-tumour antibody production as a possible mechanism
of the action of UK101. Here, too, DM abolished UK101-
stimulated cytotoxicity.
Assuming that UK101 activates the immune system against
tumours, Western blot analysis showing that it stimulates produc-
tion of antibodies directed against principally the 14- and 50-kDa
bands, and to a lesser extent the 37-kDa band, suggests that they
can constitute the most important antigenic stimulus and are
capable of unleashing an anti-tumour reaction. This may be true
even if our subcutaneous administration without Freund’s adjuvant
cannot be simply superimposed on classic immunological tech-
niques for producing antibodies like those used to produce our
rabbit antiserum. In fact, only the 50-kDa band is shown when
serum of UK-treated hamsters is used to stain UK101. This may
simply reflect the greater efficacy of higher molecular weight
protein in stimulating antibody production revealable by Western
blot analysis. It does, however, urgently require further work to
clarify the role of each UK101 fraction in stimulating the anti-
tumour immune reaction.
Our opinion is that other studies are necessary to reveal the
exact mechanism of action of the perchloric extract UK101, deter-
mine which of its fractions is active, and demonstrate or rule out
their cooperation. Nonetheless, our data provide clear evidence
that it inhibits chemically induced carcinogenesis in the Syrian
hamster and stimulates serum-mediated cytotoxicity against
tumour cells such as Kato III.
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